Status:
COMPLETED
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborating Sponsors:
The Stop ALD Foundation
Conditions:
X-linked Adrenoleukodystrophy
Adrenomyeloneuropathy
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder characterised by accumulation of very long chain fatty acids (VLCFA) in plasma and tissue. Presumably this accumulation is resp...
Eligibility Criteria
Inclusion
- an age of 18 years or older
- capable of giving informed consent and capable of visiting the hospital for follow-up visits
- no contra-indications for the use of bezafibrate, e.g. kidney- and/or liver disease.
- confirmed X-ALD, AMN phenotype (confirmed by VLCFA analysis or analysis of the ABCD1 gene)
Exclusion
- use of medication that lowers cholesterol and/or triglycerides (e.g. statins)
- liver disease or and increase in serum CK of more than 3 times the baseline level
- treatment with Lorenzo's oil in the 8 weeks preceding the trial
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01165060
Start Date
July 1 2010
End Date
August 1 2011
Last Update
August 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Academisch Medisch Centrum
Amsterdam, North Holland, Netherlands, 1100 DD